The Janus kinase (JAK) family of protein tyrosine kinases plays a pivotal role in mediating cytokine signaling, which is essential for various biological processes, including immune response, hematopoiesis, and inflammation. As we age, dysregulation of these pathways can lead to chronic inflammation, often referred to as "inflammaging" which contributes significantly to age-related diseases such as Alzheimer's disease, cardiovascular diseases, and cancers.
Fig. 1 Structural basis of JAK inhibition. (Lv Y, et al., 2024)
In recent years, the JAK/STAT pathway has emerged as a significant target in the field of anti-aging drug discovery. CD BioSciences is committed to offering tailored anti-aging drug discovery services to advance this research.
How Do We Develop JAK Inhibitors?
Our experts use advanced screening technologies to identify potential inhibitors that can modulate the JAK-STAT pathway. Using high-throughput screening and structure-based drug design, we help clients discover compounds that effectively reduce inflammation and restore normal signaling in aging tissues. We use compound libraries to analyze their potency and specificity to help our clients select potential lead candidates with minimal off-target effects.
Analysis of the Role of JAK Inhibitors in Alleviating Cellular SASPs
Using cellular senescence models, we help clients design experiments to measure the impact of JAK inhibitors on senescence-associated secretory phenotype (SASP) markers and cellular senescence markers (e.g., p16, p21). We offer transcriptomics, proteomics, and metabolomics to identify changes in gene expression, protein secretion, and metabolic pathways following JAK inhibitor treatment. Furthermore, we provide statistical analysis of SASP reduction and its correlation with improved cellular function.
Targeting JAK in Aging-Related Diseases
- Aging-related neurodegenerative diseases. In Alzheimer's and Parkinson's disease, neuroinflammation plays a crucial role in disease progression. We help clients develop anti-aging drugs targeting JAK to reduce neuroinflammatory responses, thereby protecting neuronal function and promoting cognitive health in the elderly.
- Aging-related cardiovascular diseases. Aging is characterized by increased cardiovascular risk due to chronic inflammation and endothelial dysfunction. We help clients develop anti-aging drugs targeting JAK to improve vascular health by reducing inflammatory cytokine levels.
Targeting JAK presents a groundbreaking approach to anti-aging drug discovery. CD BioSciences is committed to advancing this research through the discovery of small molecules and biologicals. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- Lv Y, et al. Small molecule drug discovery targeting the JAK-STAT pathway. Pharmacol Res, 2024, 204: 107217.
- Xu M, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A, 2015, 112 (46): E6301-10.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
